

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 1026

Column: EDITORIAL

Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease

Konstantinos Papamichail, Severine Vermeire

Abstract

Anti-tumour necrosis factor alpha (anti-TNF α) therapy is an established treatment in inflammatory bowel disease (IBD). However, this treatment is associated with high costs and the possibility of severe adverse events representing a true challenge for patients, clinicians and health care systems. Consequently, a crucial question is raised namely if therapy can be stopped once remission is achieved and if so, how and in whom. Additionally, in a real-life clinical setting, discontinuation may also be considered for other reasons

Match Overview



1	Abstract: TNF inhibitor removed with 8 matches View Report	1%
2	CrossCheck: TN inhibitor Disease, Cost, High Costs, Health Services, Health Insurance, and High Health-Care Costs View Report	1%
3	CrossCheck: TN inhibitor Pharmaceutical, Pharmaceutical Industry, Food Safety, Food Drug Administration, Gastroenterology, (IBD), (IBD), (IBD)	1%
4	Abstract: TN inhibitor removed with 8 matches View Report	<1%



Withdrawal of anti-tumour necrosis factor α therapy in inflammatory bowel disease



学术搜索

找到约 19,000 条结果 (用时0.20秒)

我的著作引用情况

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

简体中文网页

包括专利

包含引用

创建快讯

小提示: 只搜索中文(简体)结果, 可在 学术搜索设置 指定搜索语言

Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

P Rutgeerts, G D'Haens, S Targan, E Vasilias... - Gastroenterology, 1999 - Elsevier
... 6 infliximab retreatment patients), and "other" (2 placebo retreatment patients; withdrawal of consent ... One additional patient, who tested negative for anti-double-stranded DNA antibodies at the ... Tumour necrosis factor-alpha and interferon-gamma production measured at the si.
被引用次数: 1032 相关文章 所有 10 个版本 引用 保存

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's disease uva.nl 中的 [PDF]

SR Targan, SB Hanauer... - ... England Journal of ..., 1997 - Mass Medical Soc
... Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn's disease. ... (2014) Higher risk of tuberculosis reactivation when anti-TNF is combined with ... (2014) Early tissue responses in psoriasis to the antitumour necrosis factor- α biologic etanercept ...
被引用次数: 2881 相关文章 所有 9 个版本 引用 保存

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I Trial ucsc.edu 中的 [PDF]

SB Hanauer, WJ Sandborn, P Rutgeerts, RN Fedorak... - Gastroenterology, 2006 - Elsevier
... Tumor necrosis factor (TNF) is recognized as an important cytokine in the pathogenesis of Crohn's ... within 3 months); had previously received infliximab or any other anti-TNF therapy ... similar to those who received adalimumab (Table 1). Overall, premature withdrawal from the ...
被引用次数: 991 相关文章 所有 11 个版本 引用 保存

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial researchgate.net 中的 [PDF]

G D'Haens, S Van Deventer, R Van Hogezand... - Gastroenterology, 1999 - Elsevier
... Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's ... Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). ... A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for Crohn's ...
被引用次数: 667 相关文章 所有 8 个版本 引用 保存

网页 新闻 图片 视频 购物 更多 搜索工具

找到约 335,000 条结果 (用时 0.53 秒)

Google 学术 : Withdrawal of anti- tumour necrosis factor α therapy in inflammatory bowel disease

... safety of retreatment with anti-tumor necrosis factor ... - Rutgeerts - 被引用次数 : 1032

... cA2 to tumor necrosis factor α for Crohn's disease - Targan - 被引用次数 : 2883

Human anti-tumor necrosis factor monoclonal antibody ... - Hanauer - 被引用次数 : 992

Outcome of elective withdrawal of anti-tumour necrosis ...

www.ncbi.nlm.nih.gov/pubmed/25311864 - 翻译此页

作者 : AJ Brooks - 2014

Outcome of elective withdrawal of anti-tumour necrosis factor- α therapy in patients with Crohn's disease in established remission. Brooks AJ(1), Sebastian S(2), ...

Psoriasis associated with anti-tumour necrosis factor ...

www.ncbi.nlm.nih.gov/pubmed/21957906 - 翻译此页

作者 : G Cullen - 2011 - 被引用次数 : 71 - 相关文章

2011年9月29日 - Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the ...

Onset of psoriasis in patients with inflammatory bowel ...

www.ncbi.nlm.nih.gov/pubmed/23265148 - 翻译此页

作者 : I Guerra - 2013 - 被引用次数 : 4 - 相关文章

Anti-TNF agents are widely used in the treatment of some inflammatory diseases, such as inflammatory bowel disease and psoriasis. ... Although withdrawal of anti-TNF was usually implemented in the first reports, in more recent series ... Psoriasis/therapy; Risk Factors; Tumor Necrosis Factor-alpha/antagonists & inhibitors* ...

Anti-tumour Necrosis Factor Alpha (anti-TNF-alpha) - Patient ...

www.patient.co.uk > Professional Reference - 翻译此页